News & Updates

A survey conducted prior to resmetirom approval reports low rates of weight loss medication prescription due to low comfort potentially from lack of education despite strong beliefs that these drugs can benefit patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

Discontinuing tenofovir in antiretroviral therapy (ART) may expose people living with HIV to hepatitis B virus (HBV)-related risks, including reactivation in those previously exposed and infection in those who are susceptible, according to a systematic review and meta-analysis.

Colorectal endoscopic submucosal dissection (ESD) performed by expert endoscopists in Western older adults is safe and effective, according to a study. Outcomes are also similar to those in younger cohorts.

The use of lubiprostone as an adjunct therapy for bowel preparation results in better odds of excellent quality prep, with an acceptable safety profile, a study has shown.

In the treatment of ulcerative colitis (UC) patients with prior advanced therapy failure, subsequent treatment with upadacitinib is associated with higher remission rates compared with tofacitinib and ustekinumab, according to the retrospective TRIDENT-UC study.

Neoadjuvant immune checkpoint inhibitor (ICI) therapy demonstrates notable activity in non-metastatic deficient mismatch repair/microsatellite instability-high (dMMR/MSI) colorectal cancer (CRC), with high response rates and favourable clinical outcomes, as shown in the ongoing ambispective international observational study AGEO-NEO-MSI.

In patients with familial adenomatous polyposis (FAP), treatment with encapsulated rapamycin is safe and appears to lower polyp burden, according to a phase II study.

Treatment with STRIDE*, with or without lenvatinib, plus TACE** significantly improves progression-free survival (PFS), objective response rate (ORR), and duration of response (DoR) in patients with embolization-eligible hepatocellular carcinoma (eeHCC) compared with TACE alone, according to the phase III EMERALD-3 trial presented at ESMO GI 2026.